Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PTK/ZK Not Dead Yet; R&D Efforts May Shift To Subgroup, Novartis Says

Executive Summary

Novartis/Schering AG may shift development of their investigational colorectal cancer agent PTK/ZK 787 (valatanib) to focus on patients with elevated lactate dehydrogenase (LDH) levels, Novartis Oncology President David Epstein said June 7

You may also be interested in...



Novartis’ Signifor Seeks Controlled-Data Edge In Cushing Market At Advisory Committee

Cushing’s disease treatment Signifor (pasireotide) underwent a randomized Phase III clinical trial, while the earlier approval of competitor Corcept Therapeutics’ Korlym (mifepristone) was based on an open-label study.

From Playing It Safe To All-In: Genentech Takes Risks With Oncology Pipeline

Compared to its old oncology R&D lineup, Genentech's current cancer pipeline makes it clear that the company is embracing a new, riskier development strategy

From Playing It Safe To All-In: Genentech Takes Risks With Oncology Pipeline

Compared to its old oncology R&D lineup, Genentech's current cancer pipeline makes it clear that the company is embracing a new, riskier development strategy

Related Content

UsernamePublicRestriction

Register

PS142970

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel